Physician profile
Robert D Tague
NPI 1588740369
$3,273.62
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $402 · 2020: $294 · 2021: $620 · 2022: $882 · 2023: $638 · 2024: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,075.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,074.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,522.39 | 2021-2024 | Qulipta, Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $345.06 | 2019-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $246.52 | 2019-2023 | Arexvy |
| Allergan, INC. | $167.51 | 2020 | |
| Lilly USA, LLC | $163.61 | 2020-2024 | Mounjaro, Jardiance |
| Novo Nordisk INC | $125.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $79.87 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $76.81 | 2022-2024 | Rexulti |
| Axsome Therapeutics, INC. | $68.47 | 2024 | Auvelity |
| Aimmune Therapeutics, INC. | $63.80 | 2024 | |
| Acerus Pharmaceuticals Corporation | $55.59 | 2022 | |
| Exact Sciences Corporation | $53.46 | 2023-2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $51.84 | 2023 | Gemtesa |
| Protega Pharmaceutials INC | $40.72 | 2024 | Roxybond |
| Lundbeck LLC | $32.06 | 2024 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $30.19 | 2019 | |
| Sunovion Pharmaceuticals INC. | $26.50 | 2022 | |
| Lifescan, INC. | $21.44 | 2023 | |
| Phathom Pharmaceuticals, INC. | $20.82 | 2024 | Voquezna |
| Alnylam Pharmaceuticals INC. | $20.53 | 2024 | Givlaari |
| Amgen INC. | $17.69 | 2021 | |
| Astellas Pharma US INC | $16.50 | 2024 | Veozah |
| Amarin Pharma, INC. | $14.70 | 2020 | |
| Abbott Laboratories | $12.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.